Oral contraceptives (OCs) are associated with a small increase in premenopausal breast cancer risk, especially in parous women who use them for 4 or more years before a first full-term pregnancy, according to a new meta-analysis.
Oral contraceptives (OCs) are associated with a small increase in premenopausal breast cancer risk, especially in parous women who use them for 4 or more years before a first full-term pregnancy, according to a new meta-analysis.
Chris Kahlenborn, MD, of Altoona Hospital in Altoona, Pa., and colleagues conducted a meta-analysis of 34 studies conducted since 1980. The researchers found that OCs were associated with a slightly increased risk of breast cancer in general (OR, 1.19). In studies that provided separate data for parous and nulliparous women who used OCs, they found OR of 1.29 and 1.24, respectively. The risk was highest in parous women who used OCs for at least 4 years before a first full-term pregnancy (OR, 1.52).
"Although oral contraceptives appear to be carcinogenic, the relative risk is small and the absolute risk (excess breast cancers due to OC exposure) is very small," stated the author of an accompanying editorial. "From the perspective of epidemiology and public health, we must continue to closely follow the epidemiology of OC use and health outcomes, given the widespread use of these agents and their high potential to impact women's health in both a beneficial and deleterious manner. The current study highlights the need for a close evaluation of OC use before first full-term pregnancy..."
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More